The High Level of Tertiary Lymphoid Structure Is Correlated With Superior Survival in Patients With Advanced Gastric Cancer

Wenting He†, Dachuan Zhang‡, Hong Liu‡, Tongbing Chen‡, Jun Xie‡, Lei Peng‡, Xiao Zheng§, Bin Xu§, Qing Li‡ and Jingting Jiang‡,§,

†Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, China, ‡Department of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, China, §Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China, ‡Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, China, †Institute of Cell Therapy, Soochow University, Changzhou, China

Background: A tertiary lymphoid structure (TLS) is a crucial component of the tumor microenvironment, which reflects the anti-tumor immune response in the host. The aim of the present study was to carry out a histopathological evaluation for TLS and assess its prognostic value in gastric cancer (GC).

Methods: A total of 1,033 cases that have received a gastrectomy were reviewed, including 914 in the primary cohort and 119 in the validation cohort. TLS was assessed by optical microscopy and verified by immunohistochemistry. A total of five histopathological evaluation methods were compared in the primary cohort and validated in the validation cohort. In addition, MECA-79 and CD21 were used to verify the accuracy of the histopathological scoring system for TLS. The association among TLS, clinicopathological parameters, and patient prognosis was analyzed.

Results: TLS as assessed by morphology and immunohistochemistry were significantly correlated and consistent. The morphological evaluation of TLS was accurate. Typically, the high level of TLS was significantly correlated with tumor size (P = 0.047), histological grade (P = 0.039), pTN stage (P = 0.044), and WHO subtype (P < 0.001). In addition, TLShi was a positive indicator of overall survival, as determined by Kaplan–Meier survival (P = 0.038) and multivariate Cox regression analyses (hazard ratio = 0.794, 95% CI: 0.668–0.942, P = 0.008). According to the results, TLShi had a positive effect on the primary cohort patients with pTN stages II and III (P = 0.027, P = 0.042).

Conclusions: The histopathological evaluation of TLS was accurate. Diagnosis based solely on hematoxylin and eosin staining of the sections did not easily distinguish tumor-associated TLS. The density of TLS in the center of the tumor was found to be more indicative of patient prognosis than TLS in the invasive margin, with the levels of total TLS shown to best correlate with overall survival in patients with advanced-stage GC.

Keywords: tertiary lymphoid structure, gastric cancer, prognosis, MECA-79, tumor microenvironment
INTRODUCTION

The tumor microenvironment (TME) is the internal environment where a tumor develops and where a functional complex of interactions among tumor cells, stromal cells, and tumor-infiltrating lymphocytes (TIL) takes place. The TME status reflects the interaction between the host immune response and tumor progression. Typically, TIL is a key component in TME that reflects the anti-tumor immune response in the host. It is also crucial for suppressing cancer progression and has implications for the success of the host anti-tumor immune response against certain solid tumors (1–3). A tertiary lymphoid structure (TLS), an organ-like structure, recruits naïve T and B cells into the tumor site via chemokines or cytokines. TLS is similar to a secondary lymphoid structure (SLO) in terms of structure and function (4–7). Despite the known role of TLS in tumor progression, its formation and function in solid tumors have not been thoroughly explained so far. In recent studies, TLS has been detected in primary (8) and metastatic tumors (7), and the high density of TLS has been found to be positively correlated with the prognosis for colorectal (9), lung (10), breast cancer (11), and malignant melanoma (12). However, the mechanisms that promote an anti-tumor immune response, as well as the association between TLS and patient prognosis, in gastric cancer (GC) remain unclear (13). High endothelial venules (HEVs) are the characteristic vessels of SLO and TLS. Of note, MECA-79 (14, 15) expressed on the HEVs binds to CD62L, and its expression on lymphocytes causes the latter to roll along HEVs and infiltrate the TME (12). Based on the results from the aforementioned studies, HEVs are the crucial sites for lymphocyte recruitment and TLS accounts for an important source of TIL. The aim of the present study was to assess the distribution and the prognostic value of TLS in GC by reviewing a large number of cases. In addition, immunohistochemically stained MECA-79 and CD21 were used to verify the accuracy of the morphological TLS scoring system. The association among TLS, clinicopathological parameters, and patient prognosis was analyzed.

MATERIALS AND METHODS

Patient and Tissue Samples

In this retrospective cohort study, data were collected from the Department of Pathology of the Third Affiliated Hospital of Soochow University between 2002 and 2008. The patient inclusion criteria were as follows: (i) patients pathologically diagnosed with primary gastric adenocarcinoma, (ii) patients who were naïve to preoperative chemotherapy or radiotherapy, (iii) patients with adequate formalin-fixed and paraffin-embedded (FFPE) tissue blocks, (iv) patients with at least one slide containing the tumor invasive margin (IM), and (v) patients with complete medical records and follow-up information.

Abbreviations: TIL, tumor infiltrating lymphocytes; TME, tumor microenvironment; TLS, tertiary lymphoid structure; GC, gastric cancer; CT, center of the tumor; IM, invasive margin; pTN, pathological tumor and lymph node; LN, lymph node; OS, overall survival; AUC, area under the ROC curve.

Finally, a total of 1,033 cases were included in this study. To construct and validate the analyses for TLS, 914 patients were enrolled into the primary cohort between 2004 and 2008, while the remaining patients (119 cases) were included as the external validation cohort between 2002 and 2003. The Tumor Pathological Staging System (8th Edition) of the Union for International Cancer Control/American Joint Committee on Cancer was adopted for GC classification. The patient survival intervals were available and dated to the end of January 2018. The study protocol was approved by the Ethics Committee of Soochow University and conducted in accordance with the Declaration of Helsinki.

Histopathological Evaluation of Sections Using Hematoxylin and Eosin Staining

The aim of the present study was to evaluate the methodology for a TLS scoring system in GC. TLS evaluation was retrospectively performed using H&E staining. In brief, the tumor tissue sections were reviewed independently by four pathologists who were trained on the TLS scoring system and blinded to the clinical data. During the subsequent scoring process, any problematic case was discussed jointly by two or more of the aforementioned pathologists. No uniform standard was available for the histopathological TLS scoring system, and TLS was defined as a cumulative area of ectopic lymphocytes (>200-fold microscopic field; 1 mm in diameter). According to the criterion of previous studies (16–18), the tumor area was subdivided in the center of the tumor (CT) and the IM. Next, all available complete sections were morphologically analyzed for the (i) number of TLS and (ii) percentage of the CT or the IM region occupied by TLS in 10% increments (5 and 95% were allowed at extremes) (19). Subsequently, TLS evaluation was conducted in both the CT and the IM regions separately, and the number and the percentage were then incorporated. Following the TLS assessment, a set of TLS scores was obtained, including (i) TLS-CT number (TLS-CT-N), which indicated the number of TLS in the CT region, (ii) TLS-CT density (TLS-CT-D), which was calculated by multiplying a score of 1 with the percentage of TLS in the CT region and reflected the distribution and the density of TLS in the CT region, (iii) TLS-IM number (TLS-IM-N), which represented the number of TLS in the IM region, (iv) TLS-IM density (TLS-IM-D), which was calculated by multiplying a score of 3 with the percentage of TLS in the IM region and reflected the distribution and the density of TLS in the IM region, and (v) TLS-SUM, which indicated the TLS total score in both the CT and the IM regions (namely, the sum of TLS-CT-D and TLS-IM-D).

The Repeatability and the Accuracy of TLS Evaluation

The repeatability and the accuracy of the TLS evaluation were double-checked. First, the methodology of the TLS evaluation was obtained in the primary cohort, and the TLS evaluation was validated in the validation cohort. Secondly, immunohistochemically stained MECA-79 and CD21 were used to verify the accuracy of the morphological evaluation.
A total of 63 randomly selected cases in the primary cohort were immunologically stained for MECA-79 (1:125 dilution, RRID:AB_493556, BioLegend). HEVs, the special venules in TLS, were selected to verify the accuracy of the TLS scoring system. MECA-79 recognized the sulfate-dependent venules in TLS, were selected to verify the accuracy of the dilution, RRID:AB_493556, BioLegend). HEVs, the special HEVs. Meanwhile, 119 cases in the validation cohort were immunologically stained for MECA-79 (1:125 ethanol solutions. Cases with a positive immunohistochemical staining for MECA-79 and CD21 were considered as positive cases. The number of MECA-79+ vessels and CD21+ lymphoid follicles was recorded.

**Statistical Analysis**

IBM SPSS statistical software v24.0 (IBM Corp) and GraphPad Prism 6 (GraphPad Software) were used for the statistical analysis. Correlation analysis, χ² test, consistency test, Kaplan–Meier survival analysis, and Cox regression analysis were used as appropriate. All statistical analyses were two-sided, and P < 0.05 was considered to indicate a statistically significant difference.

**RESULTS**

**Prognostic Value of TLS in GC**

The analysis was conducted based on data from the primary cohort. To make the scoring system simpler for statistical analysis, the variables were transformed into binary variables according to the median (Supplemental Table I). As shown by the Kaplan–Meier survival analysis, high levels of TLS-CT-D or TLS-SUM were correlated with superior survival in patients (χ² = 4.013, P = 0.045; χ² = 4.298, P = 0.038, Table 1, Figure 1A). In addition, the contribution of TLS to the prognostic power of each pTN stage was evaluated (Table 1). The results suggested that TLS-SUM had a protective effect on patients with pTN stages II and III (P = 0.027, P = 0.042, Table 1, Figures 1B,C). To verify the statistical analysis results, an external validation cohort was used to test the variables. The prognostic value of TLS-SUM in the validation cohort was the same as that in the primary cohort (P = 0.024, P = 0.035, Table 1, Figures 1D–F). High levels of TLS-IM-N were correlated with better survival in pTN stage II patients from the primary and the validation cohorts (P = 0.006, P = 0.034, Table 1, Supplemental Figures 1A,B). A total of 325 cases with different levels of TLS-CT-D and TLS-IM-N were grouped: 169 TLS-CT-D^high^ TLS-IM-N^low^ cases and 156 TLS-CT-D^low^ TLS-IM-N^high^ ones. The TLS-CT-D^high^ TLS-IM-N^low^ was correlated with better survival in all patients and pTN stage I patients from the primary cohort (P = 0.031, P = 0.032, Supplemental Figures 1C,D). Cox regression analysis was performed to evaluate the prognostic significance of TLS and the clinicopathological parameters [including age, tumor size, lymph node (LN) metastasis, vessel invasion, histopathological grade, pTN stage, WHO subtypes, and sets of TLS]. In the univariate Cox regression analysis, TLS-CT-D, TLS-SUM, and all the clinicopathological parameters were found to be independent prognostic factors for overall survival. Moreover, the LN metastasis information was contained in the pTN stage parameter and excluded from the multivariate Cox regression model. The multivariate Cox regression analysis was performed based on the TLS-CT-D and the TLS-SUM data [hazard ratio (HR) = 0.833, 95% CI: 0.702–0.989, P = 0.037; HR = 0.794, 95% CI: 0.668–0.942, P = 0.008, Supplemental Table II]. Of note is that TLS had a HR score of <1, suggesting that the high level of TLS showed a protective effect on patient survival. To verify the statistical analysis, Cox regression analysis was performed in the validation cohort. In univariate and multivariate Cox regression analyses, TLS-SUM was identified as the independent prognostic factor (HR = 0.496, 95% CI: 0.252–0.973, P = 0.041; HR = 0.411, 95% CI: 0.229–0.740, P = 0.003, Table 2).

**Association Between TLS and Clinicopathological Parameters**

Details of the clinicopathological parameters, TLS-SUM, and TLS-CT-D are presented in Table 3. TLS was significantly correlated with tumor size, histological grade, pTN stage, and WHO subtype (P < 0.05, Table 2). These data revealed that the high levels of TLS were associated with clinicopathological parameters, such as smaller tumor size and earlier pTN stage, and indicated better prognosis. TLS might serve as a potent prognostic indicator, which can be as crucial as a clinicopathological parameter.

**Accuracy of Morphological Evaluation of TLS**

According to the abovementioned analyses, TLS-SUM was screened as the representative of morphological TLS evaluation. Immunohistochemical staining of MECA-79 and CD21 was used to verify the accuracy of the morphological TLS evaluation. Based on a statistical correlation analysis, the score of TLS-SUM was positively correlated with the number of MECA-79+ vessels (r = 0.696, P < 0.001, Supplemental Table III, Figures 2A–C). In a subsequent statistical analysis, all variables were transformed into binary variables. Thereafter, all 63 patients were divided into two groups according to the presence or the absence of MECA-79+ vessels, including 40 (63.5%) MECA-79+ cases and 23 (36.5%) MECA-79− ones. According to the TLS-SUM, the 63 patients were subdivided into 44 high-level cases and 17 low-level cases. The results of the χ² test and consistency analysis revealed a significant consistency agreement between MECA-79 and TLS-SUM (χ² = 18.849, P < 0.001, κ = 0.565, P < 0.001, Supplemental Table III). The CD21-marked FDC in the B cell follicles was also used to verify the accuracy of the morphological TLS evaluation. Upon analysis, the score of TLS-SUM was positively correlated with the number of CD21+ lymphoid follicles (r = 0.924, P < 0.001, Supplemental Table III, Figures 2D–F). The patients in the validation cohort were divided into two groups, according to the median: 51 CD21^hi^ cases and 68 CD21^low^
### TABLE 1 | Hierarchical K–M survival analysis of tertiary lymphoid structure (TLS) and pathological tumor and lymph node (pTN).

| Hierarchical definition | TLS in primary (high/low) | $\chi^2$ | $P$ value | TLS in validation (high/low) | $\chi^2$ | $P$ value |
|-------------------------|---------------------------|---------|-----------|-------------------------------|---------|-----------|
|                         | Number  | Mean overall survival (OS) |         |                               | Number  | Mean OS  |
| **TLS score**           | **pTN stage**              |         |           |                               |         |           |
| **TLS-CT-N**            | I       | 133/103  | 148.6/144.0 | 0.547  | 0.460  | 14/13  | 138.6/130.3 | 0.215  | 0.643  |
|                         | II      | 114/160  | 103.6/89.0  | 3.071  | 0.080  | 11/20  | 97.0/81.5  | 0.213  | 0.645  |
|                         | III     | 223/181  | 48.3/39.5   | 2.912  | 0.088  | 24/37  | 57.9/40.1  | 1.701  | 0.192  |
|                         | III–III | 470/444  | 90.1/81.7   | 3.262  | 0.068  | 49/70  | 90.3/68.8  | 2.632  | 0.105  |
| **TLS-CT-D**            | I       | 138/97   | 148.4/144   | 0.650  | 0.420  | 12/15  | 141.7/129.1 | 0.454  | 0.500  |
|                         | II      | 119/155  | 103.4/88.4  | 3.278  | 0.070  | 11/20  | 97.0/81.5  | 0.213  | 0.645  |
|                         | III     | 225/179  | 47.7/40.2   | 2.220  | 0.136  | 25/36  | 67.7/32.4  | 5.261  | 0.022  |
|                         | I–III   | 483/431  | 90.3/81.0   | 4.013  | 0.045  | 48/71  | 93.4/66.9  | 3.401  | 0.065  |
| **TLS-IM-N**            | I       | 104/132  | 139.1/152.4 | 3.323  | 0.068  | 7/20   | 114.7/141.3 | 0.447  | 0.504  |
|                         | II      | 137/137  | 105.8/84.1  | 7.552  | 0.006  | 13/18  | 121.2/86.1  | 4.519  | 0.034  |
|                         | II–III  | 229/175  | 45.7/42.5   | 0.977  | 0.323  | 18/43  | 74.9/35.3  | 5.417  | 0.020  |
|                         | III     | 470/444  | 84.0/87.9   | 0.555  | 0.456  | 38/81  | 98.7/67.3  | 4.825  | 0.028  |
|                         | I–III   | 483/431  | 90.3/81.0   | 4.013  | 0.045  | 48/71  | 93.4/66.9  | 3.401  | 0.065  |
| **TLS-IM-D**            | I       | 106/130  | 139.6/152.1 | 7.160  | 0.007  | 17/20  | 114.9/143.1 | 0.447  | 0.504  |
|                         | II      | 138/136  | 105.4/84.3  | 0.848  | 0.357  | 14/17  | 114.9/93.3  | 3.760  | 0.053  |
|                         | III     | 230/174  | 45.5/42.6   | 0.486  | 0.498  | 39/80  | 97.6/71.8  | 4.487  | 0.034  |
|                         | I–III   | 474/440  | 84.1/87.8   | 0.486  | 0.498  | 39/80  | 97.6/71.8  | 4.487  | 0.034  |
| **TLS-SUM**             | I       | 127/109  | 145.3/148.0 | 0.001  | 0.969  | 8/19   | 122.5/140.0 | 0.191  | 0.662  |
|                         | II      | 120/154  | 105.1/87.0  | 4.866  | 0.027  | 12/19  | 127.7/60.8  | 5.126  | 0.024  |
|                         | III     | 210/194  | 49.3/38.7   | 4.153  | 0.042  | 17/44  | 76.2/35.5  | 4.424  | 0.035  |
|                         | I–III   | 457/457  | 90.7/81.1   | 4.298  | 0.038  | 37/82  | 103.7/85.9  | 5.928  | 0.015  |

Values in bold signify $p < 0.05$.

---

**DISCUSSION**

TLS, an organ-like structure of the ectopic aggregated lymphocytes, was first identified in chronic inflammation and autoimmune diseases (5–7). In such pathological structures,
### TABLE 2 | Univariate and multivariate Cox regression analyses of tertiary lymphoid structure (TLS)-SUM and clinicopathologic parameters.

| Clinicopathological parameters | Multivariate analysis in primary |  | Multivariate analysis in validation |  |
|-------------------------------|---------------------------------|-----------------|-------------------------------------|-----------------|
|                              | HR | 95% CI | P value | HR | 95% CI | P value |
| Age (≤50/>50)                 | 1.954 | 1.472–2.594 | <0.001 | 1.924 | 1.010–3.667 | 0.047 |
| Tumor size (≤5 cm/>5 cm)      | 1.101 | 0.917–1.321 | 0.303 | 1.272 | 0.740–2.189 | 0.384 |
| Vessel invasion (-/+ )        | 1.209 | 1.013–1.443 | 0.035 | 1.316 | 0.648–2.670 | 0.448 |
| Histological grade           |  |  |  |  |  |  |
| Well                          |  |  |  |  |  |  |
| Moderately                    | 0.862 | 0.414–1.794 | 0.691 | 4.122 | 0.506–33.566 | 0.186 |
| Poor                          | 1.094 | 0.520–2.301 | 0.812 | 4.525 | 0.559–37.978 | 0.164 |
| pTN (I–III)                   |  |  |  |  |  |  |
| I                             | 3.295 | 2.290–4.742 | <0.001 | 2.343 | 0.988–5.558 | 0.053 |
| II                            | 8.334 | 5.788–12.000 | <0.001 | 3.246 | 1.367–7.705 | 0.008 |
| WHO subtypes                  |  |  |  |  |  |  |
| Tubular                       |  |  |  |  |  |  |
| Mucinous                      | 0.780 | 0.579–1.052 | 0.103 | 0.636 | 0.300–1.530 | 0.239 |
| Papillary                     | 1.311 | 0.899–1.913 | 0.160 | 0.739 | 0.292–1.872 | 0.523 |
| Poorly cohesive               | 1.006 | 0.795–1.273 | 0.962 | 0.903 | 0.382–2.137 | 0.816 |
| Undifferentiated              | 1.182 | 0.861–1.624 | 0.301 | 2.207 | 1.000–4.873 | 0.050 |
| TLS-SUM (low/high)            | 0.794 | 0.668–0.942 | 0.008 | 0.411 | 0.229–0.740 | 0.003 |

Values in bold signify p < 0.05.

### TABLE 3 | Relationship between tertiary lymphoid structure (TLS) and clinicopathological parameters.

| Clinicopathological parameters | TLS-SUM | χ² | P value | TLS-CT-D | χ² | P value | TLS-IM-N | χ² | P value |
|-------------------------------|---------|----|---------|----------|----|---------|----------|----|---------|
| Age (year)                    |         |    |         |          |    |         |          |    |         |
| >50                           | 387     | 2.389 | 0.122  | 410      | 2.091 | 0.148  | 405      | 0.057 | 0.811  |
| ≤50                           | 70      | 3.942 | 0.047  | 225      | 9.599 | 0.002  | 250      | 1.212 | 0.271  |
| Tumor size (cm)               |         |    |         |          |    |         |          |    |         |
| >5                            | 220     | 3.942 | 0.047  | 225      | 9.599 | 0.002  | 250      | 1.212 | 0.271  |
| ≤5                            | 237     | 3.942 | 0.047  | 225      | 9.599 | 0.002  | 250      | 1.212 | 0.271  |
| Lymph node metastasis         |         |    |         |          |    |         |          |    |         |
| Yes                           | 271     | 2.040 | 0.153  | 290      | 1.048 | 0.306  | 299      | 1.668 | 0.196  |
| No                            | 186     | 2.040 | 0.153  | 193      | 1.048 | 0.306  | 171      | 1.668 | 0.196  |
| Vessel invasion               |         |    |         |          |    |         |          |    |         |
| Yes                           | 157     | 0.005 | 0.945  | 155      | 2.553 | 0.110  | 169      | 0.956 | 0.328  |
| No                            | 300     | 0.005 | 0.945  | 328      | 2.553 | 0.110  | 301      | 0.956 | 0.328  |
| Histological grade           |         |    |         |          |    |         |          |    |         |
| Well                          | 22      | 6.512 | 0.039  | 26       | 7.396 | 0.025  | 17       | 2.795 | 0.247  |
| Moderately                    | 146     | 6.512 | 0.039  | 155      | 7.396 | 0.025  | 165      | 2.795 | 0.247  |
| Poor                          | 289     | 6.512 | 0.039  | 302      | 7.396 | 0.025  | 288      | 2.795 | 0.247  |
| pTN stage                     |         |    |         |          |    |         |          |    |         |
| I                             | 127     | 6.226 | 0.044  | 139      | 14.531 | 0.001  | 104      | 9.808 | 0.007  |
| II                            | 120     | 6.226 | 0.044  | 119      | 14.531 | 0.001  | 137      | 9.808 | 0.007  |
| III                           | 210     | 6.226 | 0.044  | 225      | 14.531 | 0.001  | 229      | 9.808 | 0.007  |
| WHO subtypes                  |         |    |         |          |    |         |          |    |         |
| Tubular                       | 296     | 24.119 | <0.001 | 309      | 15.867 | 0.003  | 304      | 7.781 | 0.100  |
| Mucinous                      | 37      | 47   | 38      | 40      | 45  | 32 |
| Papillary                     | 9       | 13   | 35      | 16      | 32  | 30 |
| Poorly cohesive               | 84      | 85   | 61      | 78      | 68  | 30 |
| Undifferentiated              | 31      | 29   | 33      | 32      | 30  | 30 |
tissues that harbor tumor antigens are infiltrated by cellular or molecular effectors of the immune system, which are then organized anatomically and functionally as those in SLO with B follicles and T-zone formation (9). TLS is a potential functional immune site for T lymphocyte activation, B cell maturation, and antibody production. According to recent studies, TLS has been detected in various tumors and found to be associated with favorable prognosis (7–12, 20–22). Nonetheless, there are no uniform histopathological diagnostic standards for TLS, and the prognostic value of TLS distribution remains unclear in the field of GC (4, 13). In the present study, a set of TLS scores was obtained by reviewing the H&E-stained sections. Based on the immunohistochemical detection of MECA-79 and CD21, the morphological TLS evaluation was accurate, which was verified by the external validation testing. By comparing the TLS between the CT and the IM regions, it was found that the presence of TLS in the CT region was correlated with better prognosis than that in the IM region, which was a novel finding. The gastric wall is anatomically classified into four layers: mucosa, submucosa, muscular layer, and serosa. The submucosa and the subserosa contain loose connective tissue as well as normal lymph nodes and ectopic lymphoid aggregates under homeostatic conditions as part of the digestion-associated lymphoid tissues, which play an essential role in the gastrointestinal immune response. The IM region located in the submucosa and the subserosa correspond to pTN stage I or III. In these two layers, the TLS may be associated with tumors or pre-exist, making them hard to distinguish using H&E-staining-based diagnosis. On the contrary, the muscular layer is composed of smooth muscle and barely contains lymphatic tissue in the normal gastric tissue. The IM region located in the muscular layer corresponding to pTN stage II and the TLS-IM were mainly associated with tumors in GC tissue. The results of the hierarchical Kaplan–Meier analysis confirmed this. High levels of TLS-IM were correlated with better survival in pTN stage II patients, but no correlation with survival was identified in pTN stages I–III patients. TLS-CT-D^high TLS-IM-N^low was correlated with better survival in all patients and in pTN stage I patients. Therefore, it is necessary that the ability to make this distinction be improved in future studies.

The formation and the function of TLS in solid tumors have not yet been thoroughly explained. At the cancer site, TLS may trigger a cancer-associated inflammation, and it is a crucial site for the production of antibodies that exert important effects on the polarization of macrophages and myeloid cells (23); this way, the derived suppressor cells promote cancer progression (24). Conversely, the antitumor immune response originating from TLS can potentially control tumor invasion and metastasis, which can thus enhance the efficiency and the specificity of T-cell priming and boost a faster T-cell reaction to tumor antigens in situ (9, 25). In addition, the present study also showed that TLS-SUM and TLS-CT-D were significantly correlated with tumor size, pTN stage, and histological grade. According to the above results, TLS^hi was associated with better prognosis for GC patients since TLS was a potential regulatory factor of tumor progression and metastasis. Malignant tumors were treated under the standard therapeutic guidelines based
REFERENCES

1. Chen LJ, Sun J, Wu HY, Zhou SM, Tan Y, Tan M, et al. B7-H4 expression associates with cancer progression and predicts patient’s survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother. (2011) 60:1047–55. doi: 10.1007/s00262-011-1017-3

2. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. (2013) 39:782–95. doi: 10.1016/j.immuni.2013.10.003

3. Friedman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. (2012) 12:298–306. doi: 10.1038/nrc3245

4. Schlosser HA, Thelen M, Lechner A, Wennhold K, Garcia-Marquez MA, Rothschild SI, et al. B cells in esophageal-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies. Oncoimmunology. (2019) 8:e1512458. doi: 10.1080/2162402X.2018.1512458

5. Drayton DL, Liao S, Mounzer RH, Ruddle NH. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol. (2006) 7:344–353. doi: 10.1038/ni1330

6. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol. (2006) 6:205–17. doi: 10.1038/nri1786

7. Dieu-Nosjean MC, Goc J, Giraldo NA, Sautes-Fridman C, Fridman WH. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. (2014) 35:571–80. doi: 10.1016/j.it.2014.09.006

8. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. (2008) 26:4410–7. doi: 10.1200/JCO.2007.15.0284

9. Bergomas F, Grizzi F, Doni A, Pesce S, Laghi L, Allavena P, et al. Tertiary intratumor lymphoid tissue in colo-rectal cancer. Cancers (Basel). (2011) 4:1–10. doi: 10.3390/cancers4010001

10. de Chaisemartin I, Goc J, Damotte D, Validire P, Magdeleine P, Alifano M, et al. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res. (2011) 71:6391–8. doi: 10.1158/0008-5472.CAN-11-0952

DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the article/Supplementary Material.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The Ethics Committee of Soochow University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

WH and DZ: conception and design of the study. DZ, TC, JX, and LP: collection and assembly of data. XZ, HL, and BX: statistical analysis of data. JJ and QL: study supervision. WH and DZ: drafting of the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by grants from the National Natural Science Foundation of China (No. 31701111), the Program for Youth Talents of the Health Commission of Changzhou (QN201905).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.00980/full#supplementary-material

Supplemental Figure 1 | The Kaplan–Meier survival analysis of TL-IM-N at pTN stage II from the primary cohort (A) and the validation cohort (B). According to the TLS-CT-D and the TLS-IM-N, the patients were divided into TLS-CT-D<sub>high</sub> and TLS-CT-D<sub>low</sub> and TLS-IM-N<sub>high</sub> and TLS-IM-N<sub>low</sub>. The Kaplan–Meier survival curves for pTN stages I–III patients (C) and pTN stage I patients (D) from the primary cohort are shown.

Supplemental Table I | Subgroup detail of histopathological evaluation of TLS.

Supplemental Table II | Multivariate Cox Regression Analyses of TLS scores.

Supplemental Table III | Relationship between TLS-SUM and MECA-79 for HEVs.
11. Martinet L,Filleron T, Le Guelllec S, Rochaix P, Garrido I, Girard JP. High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotxin beta-producing dendritic cells in human breast cancer. J Immunol. (2013) 191:2001–8. doi: 10.4049/jimmunol.1300872

12. Cipponi A, Mercier M, Seremet T, Baurain J, Theate I, van den Oord J, et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res. (2012) 72:3997–4007. doi: 10.1158/0008-5472.CAN-12-1377

13. Tanaka H, Tamura T, Okita Y, Yoshii M, Tokumoto M, Go Y, et al. Significance of immune-cell infiltration in gastric. Gastric Cancer. (2018) 45:217–21.

14. Turcotte S, Gros A, Tran E, Lee CC, John WR, Robbins PF, et al. Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin Cancer Res. (2013) doi: 10.1158/1078-0432.CCR-13-1736

15. Bento DC, Jones E, Junaid S, Tull J, Williams GT, Godkin A, et al. High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression. Oncoimmunology. (2015) 4:e974374. doi: 10.4161/2162402X.2014.974374

16. Zhang D, He W, Wu C, Tan Y, He Y, Xu B, et al. Scoring system for tumor-infiltrating lymphocytes and its prognostic value for gastric cancer. Front Immunol. (2019) 10:71. doi: 10.3389/fimmu.2019.00071

17. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer. (2003) 41:2645–54. doi: 10.1016/j.ejca.2005.07.017

18. Saldaňa G, Flatman K, Teo KW, Bamford M. A novel numerical scoring system for melanoma tumor-infiltrating lymphocytes has better prognostic value than standard scoring. Am J Surg Pathol. (2017) 41:906–14. doi: 10.1097/PAS.000000000000848

19. Petitprez F, de Reynies A, Keung EZ, Chen TW, Sun CM, Calderaro J, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. (2020) 577:556–60. doi: 10.1038/s41586-019-1906-8

20. Helmingk RA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. (2020) 577:549–55.

21. Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Miträ S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. (2020) 577:561–5. doi: 10.1038/s41586-019-1914-8

22. Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell. (2010) 17:121–34. doi: 10.1016/j.ccr.2009.12.019

23. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. (2008) 454:436–44. doi: 10.1038/nature07205

24. Zhang Z, Zhu Y, Wang Z, Zhang T, Wu P, Huang J. Yin-yang effect of tumor infiltrating B cells in breast cancer: from mechanism to immunotherapy. Cancer Lett. (2017) 393:1–7. doi: 10.1016/j.canlet.2017.02.008

25. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. (2007) 450:903–7. doi: 10.1038/nature06309

26. Donnem T, Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, et al. Stromal CD8+ T-cell density-a promising supplement to TNM staging in non-small cell lung cancer. Clin Cancer Res. (2015) 21:2635–43. doi: 10.1158/1078-0432.CCR-14-1905

27. Goff SL, Smith FO, Klapper JA, Sherry R, Wunderlich JR, Steinberg SM, et al. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother. (2010) 33:840–7. doi: 10.1097/CJI.0b013e3181505b91

28. Kivistö P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, et al. TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients. Oncoimmunology. (2012) 1:409–18. doi: 10.4161/onci.18851

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 He, Zhang, Liu, Chen, Xie, Peng, Zheng, Xu, Li and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.